Always good to have more treatment options. This moving into phase 3 clinical trials. It's another small molecule, inside the cell acting medicine. So, like xeljanz it isn't a biologic but equally potent as they are.
The ABX464 molecule was shown to be effective in patients refractory to conventional treatments and, importantly, also in patients with inadequate response, loss of response, or intolerance to biologics and/or JAK inhibitors.
ABX464 has the ability to selectively upregulate miR-124 a potent anti-inflammatory micro-RNA, which down-regulates pro-inflammatory cytokines and chemokines, thereby “putting a brake” on inflammation. Thus, the molecule modulates the endogenous immune system to dampen the infla-mmation and control the symptoms. https://www.openaccessgovernment.org/changing-the-treatment-paradigm-in-inflammatory-bowel-diseases/120344/